Nuclear Medicine in Oncology

Alison Dorothy Murray, Margaret E Brooks

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role of the nuclear medicine department in the diagnosis and management of malignant disease is constantly evolving. For example, the development of new radiopharmaceuticals, such as indium-111-labelled octreotide (pentetreotide), has enabled more specific imaging for the diagnosis of gastroentero-pancreatic (GEP) endocrine tumours to be carried out. New techniques such as sentinel lymph node localisation and biopsy now allow less invasive tumour staging. Advances in chemotherapy necessitate careful monitoring of the effects of chemotherapeutic drugs on normal organ function during follow-up, and tumour specific radiopharmaceuticals are being used for non-invasive, targeted tumour therapy. Nuclear medicine investigations should always be interpreted in the knowledge of results of other imaging investigations if they are to have greatest impact on patient care.

Original languageEnglish
Pages (from-to)110-119
Number of pages10
JournalJournal of the Royal College of Surgeons of Edinburgh
Volume45
Issue number2
Publication statusPublished - Apr 2000

Fingerprint

Nuclear Medicine
Radiopharmaceuticals
Sentinel Lymph Node Biopsy
Neoplasms
Neoplasm Staging
Disease Management
Patient Care
Drug Therapy
Pharmaceutical Preparations
Therapeutics

Keywords

  • oncology
  • radiopharmaceuticals
  • diagnosis
  • staging
  • therapy
  • follow-up

Cite this

Nuclear Medicine in Oncology. / Murray, Alison Dorothy; Brooks, Margaret E.

In: Journal of the Royal College of Surgeons of Edinburgh, Vol. 45, No. 2, 04.2000, p. 110-119.

Research output: Contribution to journalArticle

@article{886298b95e254fc197241d50d1e84783,
title = "Nuclear Medicine in Oncology",
abstract = "The role of the nuclear medicine department in the diagnosis and management of malignant disease is constantly evolving. For example, the development of new radiopharmaceuticals, such as indium-111-labelled octreotide (pentetreotide), has enabled more specific imaging for the diagnosis of gastroentero-pancreatic (GEP) endocrine tumours to be carried out. New techniques such as sentinel lymph node localisation and biopsy now allow less invasive tumour staging. Advances in chemotherapy necessitate careful monitoring of the effects of chemotherapeutic drugs on normal organ function during follow-up, and tumour specific radiopharmaceuticals are being used for non-invasive, targeted tumour therapy. Nuclear medicine investigations should always be interpreted in the knowledge of results of other imaging investigations if they are to have greatest impact on patient care.",
keywords = "oncology, radiopharmaceuticals, diagnosis, staging, therapy, follow-up",
author = "Murray, {Alison Dorothy} and Brooks, {Margaret E}",
year = "2000",
month = "4",
language = "English",
volume = "45",
pages = "110--119",
journal = "Journal of the Royal College of Surgeons of Edinburgh",
issn = "0035-8835",
publisher = "Edinburgh University Press",
number = "2",

}

TY - JOUR

T1 - Nuclear Medicine in Oncology

AU - Murray, Alison Dorothy

AU - Brooks, Margaret E

PY - 2000/4

Y1 - 2000/4

N2 - The role of the nuclear medicine department in the diagnosis and management of malignant disease is constantly evolving. For example, the development of new radiopharmaceuticals, such as indium-111-labelled octreotide (pentetreotide), has enabled more specific imaging for the diagnosis of gastroentero-pancreatic (GEP) endocrine tumours to be carried out. New techniques such as sentinel lymph node localisation and biopsy now allow less invasive tumour staging. Advances in chemotherapy necessitate careful monitoring of the effects of chemotherapeutic drugs on normal organ function during follow-up, and tumour specific radiopharmaceuticals are being used for non-invasive, targeted tumour therapy. Nuclear medicine investigations should always be interpreted in the knowledge of results of other imaging investigations if they are to have greatest impact on patient care.

AB - The role of the nuclear medicine department in the diagnosis and management of malignant disease is constantly evolving. For example, the development of new radiopharmaceuticals, such as indium-111-labelled octreotide (pentetreotide), has enabled more specific imaging for the diagnosis of gastroentero-pancreatic (GEP) endocrine tumours to be carried out. New techniques such as sentinel lymph node localisation and biopsy now allow less invasive tumour staging. Advances in chemotherapy necessitate careful monitoring of the effects of chemotherapeutic drugs on normal organ function during follow-up, and tumour specific radiopharmaceuticals are being used for non-invasive, targeted tumour therapy. Nuclear medicine investigations should always be interpreted in the knowledge of results of other imaging investigations if they are to have greatest impact on patient care.

KW - oncology

KW - radiopharmaceuticals

KW - diagnosis

KW - staging

KW - therapy

KW - follow-up

M3 - Article

VL - 45

SP - 110

EP - 119

JO - Journal of the Royal College of Surgeons of Edinburgh

JF - Journal of the Royal College of Surgeons of Edinburgh

SN - 0035-8835

IS - 2

ER -